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BACKGROUND: Although therapeutic drug monitoring
has improved the clinical use of immunosuppressive
drugs, there is still interpatient variability in efficacy
and toxicity that pharmacodynamic monitoring may
help to reduce. To select the best biomarkers of tacroli-
mus pharmacodynamics, we explored the strength and
variability of signal transduction and the influence of
polymorphisms along the calcineurin pathway.
METHODS: Peripheral bloodmononuclear cells from 35
healthy volunteers were incubated with tacrolimus
(0.1–50 ng/mL) and stimulated ex vivo. Inhibition of
NFAT1 (nuclear factor of activated T cells 1) translo-
cation to the nucleus and intracellular expression of
interleukin-2 in CD4 and CD8 T cells and the sur-
face activation marker CD25 in CD3 cells were mea-
sured by flow cytometry. We sequenced the promoter
regions of immunophilins and calcineurin subunits
and characterized selected single nucleotide polymor-
phisms in the genes of the calcineurin pathway with
allelic discrimination assays.
RESULTS: All responses closely fitted an I/Imax sigmoid
model. Large interindividual variability (n30) in I0 and
IC50 was found for all biomarkers. Moreover, strong and
statistically significant associations were found between
tacrolimus pharmacodynamic parameters and polymor-
phisms in the genes coding cyclophilin A, the calcineurin
catalytic subunit  isoenzyme, and CD25.
CONCLUSIONS: This study demonstrates the consistency
and large interindividual variability of signal transduc-
tion along the calcineurin pathway, as well as the strong
influence of pharmacogenetic polymorphisms in the
calcineurin cascade on both the physiological activity
of this route and tacrolimus pharmacodynamics.
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The clinical management of calcineurin inhibitors
(CNIs)7 in organ transplantation is complex owing to
their narrow therapeutic range and poor correlation
between trough blood concentrations and clinical re-
sponse. Efficacy and toxicity are influenced bymultiple
factors and require tailoring the dose to each patient.
Pharmacodynamic (PD) monitoring is expected to
contribute to such fine tuning, as it focuses on drug
biological effects. It must be based on biomarkers ca-
pable of quantitatively reflecting the effects of a given
drug on its target, whether it is administered alone or in
combination, as well as of predicting the clinical re-
sponse to the drug.
Different PD markers of calcineurin (CaN) inhi-
bition have been examined (1, 2 ), sometimes showing
association with CNI exposure and/or clinical out-
come, but none have been fully validated in clinical
practice yet, and the measurement of most requires
long and cumbersome workup (1, 3 ). However, no
study has investigated all the possible PD biomarkers
along the calcineurin/nuclear factor of activated T cells
(NFAT) pathway. The knowledge of the strength and
variability of signal translation along this pathway, as
well as of the steps where sources of internal (genetic)
or external variability are the most influential, would
help to select the best PD biomarkers, i.e., those with
high specificity for CaN inhibition and most affected
by interindividual variability. On the other hand, very
little is known about the influence on CNI effects of
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polymorphisms in the genes coding the different pro-
teins involved.
The present study aimed at finding clues for the
rational choice of a specific biomarker or set of bio-
markers to monitor tacrolimus (TAC) immunosup-
pressive activity, reflecting its interindividual variabil-
ity, and at exploring the potential pharmacogenetic
sources of such variability.
Materials andMethods
STUDY DESIGN AND SUBJECTS
In this noninterventional study approved by the Centre
Hospitalier Universitaire (CHU) Limoges ethics review
board, 30 healthy adult volunteers who were not on
chronic treatment (except for oral contraceptive agents)
andhadnot takendrugs in thedaysprecedingblood sam-
pling gave their written informed consent to provide a
50-mL blood sample to the CHU Limoges biobank.
In addition, 5 healthy volunteers from Montevideo
gave their written informed consent to provide a 50-mL
blood sample for additional experiments regarding ana-
lytical and intraindividual variability, as part of the Phar-
macodynamic Relationships of Calcineurin Inhibitors
Cyclosporine and Tacrolimus in Liver Transplant Recip-
ients (3PIGREF) noninterventional study (ClinicalTrials.
gov ref. no. NCT01760356), approved by the Scientific
and Ethics Committee for Medical Research of the Hos-
pital Central de las Fuerzas Armadas; the Ethics Commit-
tee of the School of Chemistry of the Universidad de la
Repu´blica; and the Uruguayan Directorate of Medical
TechnologiesofHealthof theMinistryofHealth, inMon-
tevideo, Uruguay.
All investigations complied with the International
Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human
Use guidelines for Good Clinical Practice and Good Lab-
oratory Practice and with the Declaration of Helsinki.
PHARMACODYNAMIC INVESTIGATIONS
Amore detailed description of each of the following pro-
cedures is provided in the online SupplementalMethods,
which accompanies the online version of this article at
http://www.clinchem.org/content/vol60/issue10.
In vitro peripheral blood mononuclear cell stimulation.
Fifty milliliters of blood was drawn under fasting con-
ditions into sodium heparin vacutainer tubes (Becton
Dickinson), and the fresh peripheral bloodmononuclear
cell (PBMC) fraction was obtained by use of lymphocyte
density-gradient separation. Cells were resuspended in
1 supplemented RPMI 1640. For each set of markers,
aliquots of 1 106 PBMC/mLwere incubated ex vivo for
30 min at 37 °C in a humidified atmosphere at 5% CO2
(in 96-well sterile plates) with 0–50 ng/mL TAC.
Intracellular interleukin-2 expression in CD4 and
CD8 T cells. Cells were further stimulated with 50
ng/mL phorbol 12-myristate 13-acetate (PMA), 2.5
g/mL calcium ionophore, and 1g/mLGolgiPlug for
5 h at 37 °C in a humidified atmosphere with 5% CO2.
Cells were labeled with anti-CD3, anti-CD4, and anti-
CD8 antibodies; after fixation and permeabilization, they
were stainedwith a labeled anti–interleukin-2 (anti–IL-2)
antibody.
IL-2R expression at the surface of CD3 T cells. Cells
were incubated for at least 72 h at 37 °C and 5%CO2 in
the presence of 7.5 g/mL concanavalin A. PBMCs
were washed and stained with labeled anti-CD3, anti-
CD4, anti-CD8, and anti-CD25 antibodies.
NFAT1 translocation to the nucleus of PBMC. To assess
the degree of NFAT1 translocation to the nucleus, we
used an indirect antibody staining method. PBMC ali-
quots were then incubated in 50 ng/mL PMA and 2.5
g/mL calcium ionophore for another 30 min at 37 °C
and 5% CO2. Cells were washed with cold 1 PBS,
further incubated for 30 min on ice with PIPES lysis
buffer, pH 7.4, washed again, incubated with 2 anti-
NFAT1 antibodies, and stained with an IgG-
phycoerythrin antibody. We measured the resulting
fluorescent signal of labeled PBMC nuclei by flow cy-
tometry and used themeanNFAT1 fluorescence inten-
sity in the separated nuclei for statistical analysis.
We measured the inhibition of NFAT1 nuclear
translocation, the intracellular expression of IL-2 in
CD4 and CD8 subsets, and the percentage of T lym-
phocytes expressingCD25using a LSRII Fortessa® flow
cytometer equippedwith 3 lasers (BectonDickinson). All
determinationswereperformedbyuse of 106white blood
cells.Cell populationsweregated toacquire at least 50 000
CD4T lymphocytes, or 50 000PBMCnuclei forNFAT1
measurement. For each healthy volunteer, we used un-
stimulated, labeled PBMC aliquots as controls.
PHARMACOGENETIC INVESTIGATIONS
Promoters sequencing.DNA from the 30 healthy volun-
teers of themain studywas sequenced for the promoter
region of PPIA [peptidylprolyl isomerase A (cyclophi-
lin A)],8 PPP3R1 (protein phosphatase 3, regulatory
subunit B, ), PPP3CA (protein phosphatase 3, cata-
lytic subunit,  isozyme), PPP3CB (protein phospha-
8 Human genes: PPIA, peptidylprolyl isomerase A (cyclophilin A); PPP3R1, protein
phosphatase 3, regulatory subunit B, ; PPP3CA, protein phosphatase 3,
catalytic subunit,  isozyme; PPP3CB, protein phosphatase 3, catalytic subunit,
 isozyme; FKBP1A, FK506 binding protein 1A, 12 kDa; CALM1, calmodulin 1
(phosphorylase kinase, ); IL2, interleukin-2; IL2RA, interleukin 2 receptor, ;
JUN, jun proto-oncogene; NFATC1, nuclear factor of activated T-cells, cytoplas-
mic, calcineurin-dependent 1.
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tase 3, catalytic subunit,  isozyme), and FKBP1A
(FK506 binding protein 1A, 12 kDa) to investigate
polymorphisms that could modulate DNA transcrip-
tion or mRNA stability (see online Supplemental
Methods).
Genotyping assays. We selected polymorphisms in
genes involved in the calcineurin pathway if their
minor allele frequency (http://www.1000genomes.
org) was at least 10% and they had been significantly as-
sociatedwith clinical effects in at least 2 independentpub-
lished reports. Accordingly, CALM1 [calmodulin 1
(phosphorylase kinase, )] rs12885713; IL2 (interleukin-
2) rs2069762; IL2RA (interleukin 2 receptor, )
rs7090530, rs10795791, rs11594656, rs35285258; JUN
(jun proto-oncogene) rs2760501, rs4646999; and
NFATC1 (nuclear factor of activated T-cells, cytoplasmic,
calcineurin-dependent 1) rs754093 were genotyped by
means of Taqman® allelic discrimination assays with a
Rotor-Gene Q 2plex HRM (Qiagen), according to the
manufacturer’s protocol. We designed customized as-
says when required.
STATISTICAL METHODS
We tested distribution normality using the Shapiro–
Wilk test and, when needed, data were log-
transformed. Flow cytometry results were analyzed vs
the logarithm of TAC concentration by use of sigmoid
inhibition models (GraphPad PRISM®, version 5.02),
to derive basal activity (I0), 50% inhibitory concentra-
tion (IC50), and maximal inhibition (Imax). IL-2 in
CD4 and CD8 cells and CD25 in CD3 cells were
studied as a function of NFAT1 expression by use of a
large variety of models classically used for enzyme in-
hibition or receptor response, as well as simpler linear
and nonlinear regression models. In all cases, we eval-
uated goodness of fit using nonparametric tests.
The influence of gene polymorphisms was tested
by use of R version 2.15.1 (R foundation for statistical
computing, http://www.r-project.org). Conformity of
genotyping data with Hardy–Weinberg equilibrium
was verified by use of the Fisher exact test with the
“SNPassoc” package. Linkage disequilibrium was in-
vestigated for rs72174030, rs4347819, and rs4519508
(PPP3R1, chromosome 2) and for rs10795791,
rs11594656, and rs35285258 (IL2RA, chromosome
10), and the most probable haplotypes were inferred
with the “haplo.stat” package. The relations between
single nucleotide polymorphisms (SNPs) or haplo-
types and pharmacodynamic parameters (I0, IC50, and
Imax) of the respective phenotypes were investigated by
use of multiple linear regression. We compared reces-
sive, dominant, and log-additive models on the basis of
the Akaike information criterion. SNPs or haplotypes
characterized by P 0.05were included in an intermedi-
atemultivariatemodel and retained in the finalmultivar-
iate models only if they survived backward selection on
thebasis of theAkaike information criterion.TheBonfer-
roni correctionwas applied to the finalmodels to account
formultiple testing.We estimated the percentage of vari-
ability explained by the SNPs or haplotypes in these final
models through their R2 coefficients.
Results
Thirty-five healthy volunteers [15 men and 20 women,
ages 36 (10) years] were enrolled. None was taking med-
ications (except possibly oral contraceptive agents), and
all blood was collected under fasting conditions.
ANALYTICAL AND INTRAINDIVIDUAL VARIABILITY
ANOVAwas used to avoid the effect of interindividual
variability. Results are expressed as mean and CV of
log-transformed data (Table 1).
For the intraassay variability, CVs at physiological
levels (I0) were always9%, whereas those at 5 ng/mL
TAC (i.e., approximately at the IC50 concentration)
were somewhat higher, ranging from 1.5% to 11%,
with the notable exception of IL-2 inCD8 cells, which
apparently peaked at 62%. This last result probably re-
sulted from complete or almost complete inhibition of
Table 1. Analytical and intraindividual variability of biomarker measurements.
PD biomarker
Analytical variability Intraindividual variability
I0 (log10 transformed)
Effect at 5 ng/mL TAC
(log10 transformed) I0 (log10 transformed) IC50 (log10 transformed)
NFAT1 (MFI) 1.1 1.5 6.3 50
IL-2CD4 (%) 2.2 8.6 4.7 8.6
IL-2CD8 (%) 8.9 62 6.5 17
CD25CD3 (%) 6.3 11 3.2 14
a Data are CV values in percent.
b MFI, mean fluorescence intensity.
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IL-2CD8 expression at 5 ng/mL TAC (2% and
often undetectable).
The intraindividual variability estimated in 3 dif-
ferent healthy volunteers ranged from3.2% to 6.5% for
I0 and from 8.6% to 17% for IC50, except for NFAT1
(IC50 CV 50%).
PHARMACODYNAMIC PARAMETERS AND VARIABILITY
The mean fluorescence intensity of PBMC nuclei ex-
pressing NFAT1 after ex vivo incubation with stimu-
lants clearly showed the inhibitory effect of TAC. On-
line Supplemental Fig. 1 presents a typical histogram at
0 (blank) and 5 ng/mL TAC, respectively.
NFAT1 in PBMC nuclei, as well as IL-2 and CD25
responses in each T cell subpopulation, were ade-
quately fitted by I/Imax sigmoid models. The best and
worst fits obtained among the 35 healthy volunteers are
displayed in Fig. 1, showing that reliable PDparameters
could be derived from these inhibition curves. The di-
versity of physiological (I0) levels and PD responses to
TAC is illustrated in Fig. 2 for NFAT1 and in online
Supplemental Figs. 2 and 3 for IL-2 and CD25.
After log transformation of all parameters (as most
were not normally distributed), mild to moderate inter-
individual variability (CV11% to 20%)was found for the
physiological level (I0) of all the biomarkers tested, as well
as for NFAT1 and CD25 Imax values (CV 14.3% and
13.9%, respectively),whereasmuch larger interindividual
variability was found for IL-2 Imax in CD4
 and CD8
cells (CV 70.6% and 195%, respectively) (Table 2).
At Imax, 17%–83% of PBMC nuclei still expressed
NFAT1, 0%–18% CD4 and 0%–62% CD8 T lym-
phocytes expressed IL-2, and 29%–71% of CD3
T cells expressed CD25 on their membrane.
The IC50 of each biomarker increased along the
CaN pathway, from a geometric mean of 1.3 ng/mL for
NFAT1 to 4.8 ng/mL for CD25 (Table 3). Individual
IC50 values varied in a 1000-fold range for NFAT1 and
CD25, 2000-fold for IL-2 in CD4 cells, and 10 000-
fold for IL-2 in CD8 lymphocytes.
Among all the models tested (I/Imax, Michaelis–
Menten, Hill, linear, exponential, and many others) to
describe the relationships between the expression of
NFAT1 in PBMC nuclei on the one hand and the re-
sponse of IL-2 in CD4 and CD8 cells and CD25 in
CD3 cells on the other, only the allosteric sigmoidal
model showed very good fits (Spearman test) in most
volunteers (see online Supplemental Fig. 4).
PHARMACOGENETIC–PHARMACODYNAMIC RELATIONSHIPS
A complete linkage disequilibrium was found between
rs72174030, rs4347819, and rs4519508 (chromosome
2, PPP3R1) and between rs10795791, rs11594656, and
rs35285258 (chromosome 10, IL2RA) (see online Sup-
plemental Table 1).
Associations between SNPs or haplotypes on the one
hand, and phenotypes on the other (NFAT1PBMC
Nucleus, IL-2CD4, IL-2CD8, and CD25
CD3), are presented in Table 4. As 12 multivariate
models were constructed, Bonferroni correction was
applied. Interestingly, the IL2RA haplotype accounted
for 45% of IL-2CD4 I0 variability and for 84% of
CD25CD3 I0 variability (corrected P  0.0119 for
both). PPP3CA rs45441997 explained 23% of IL-
2CD4 Imax variability (corrected P  0.0280), and
PPIA rs8177826 CG explained 37% of NFAT1 IC50
variability (corrected P 0.0420).
Discussion
This ex vivo PD study in PMBCs from healthy volun-
teers showed that NFAT1, IL-2, and CD25 all re-
sponded to TACCaN inhibition following I/Imax mod-
els, in line with previous reports (4–12), with
moderate interindividual variability of physiological
levels (I0) butmuch higher variability of the PDparam-
eters IC50 and Imax.
IL-2 and CD25 response to the inhibition of NFAT1
expression in PBMCnuclei followed an allosteric sigmoi-
dalmodel,which is consistentwith tight signal translation
along the calcineurin pathway. This is the first time this
signaling cascade has been fully explored dynamically in
humans and that a strong influence of pharmacogenetic
polymorphisms is shown on both the physiological activ-
ity of this pathway and TAC pharmacodynamics.
Contrary to most previous studies on PDmarkers
of CNIs, we simultaneously investigated the different
steps of the CaN pathway to evaluate the reliability and
variability of signal transduction. Indeed, PD is a con-
tinuum between drug concentration at its site of action
and clinical outcomes, going through drug effect on its
target protein, target cell response, modifications of cell–
cell interactions, pathophysiological response (such as the
diminution of the immune response in the present case),
and finally therapeutic effects, body dysfunctions, or ac-
quireddiseases (e.g., organpreservation,malignancies, or
infectious diseases, respectively) (2). A satisfactory PD
biomarker would probably be a good intermediate be-
tween target site drug concentrations and at least 1 of the
clinical outcomes, integrating drug intrinsic activity,
pathophysiological regulation, and environmental influ-
ences. To integrate the regulation factors or environmen-
tal influences in addition to drug effect, such ideal bio-
markers should show higher interindividual variability
than the measurement of the direct drug–target protein
interaction. Thus this study focused not only on the drug
concentration–biomarker relationships, but also on the
interindividual physiological and pharmacodynamic
Tacrolimus PD and PGx in Human Lymphocytes
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Fig. 1. Modeling of the fluorescence intensity of biomarkers vs TAC concentration with the sigmoid I/Imax model.
The best (A, C, E, G) and worst (B, D, F, H) fits obtained are shown for NFAT1 (A, B); CD25 (C, D); and IL-2 (E, F, G, H). MFI,
mean fluorescence intensity.
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variability of these potential biomarkers, as well as on the
potential pharmacogenetic sources of such variability.
The specificity of our markers was ensured by the
design of our experiments, cell subsets, antibodies and
fluorochromes, and gating strategies. The limits of de-
tection, determined by the principle of fluorescence-
minus-1 controls, were 0.18% for IL-2CD4, 0.25%
for IL-2CD8, and 0.25% for NFAT1.
Previous articles have studied NFAT translocation
to the nucleus by means of multispectral image stream
flow cytometer (13, 14), but this is the first time that
NFAT1 nuclear translocation was measured by con-
ventional flow cytometry, with overall low tomoderate
intraassay variability, consistent with previous reports
(4, 6, 7, 9, 15, 16), although comparisons are difficult
owing to different markers, cell types, and experimen-
tal schemes. The other biomarkers were also measured
with good intraassay precision, except for IL-2 in
CD8 cells at 5 ng/mL TAC. However, the very high
analytical CV found in this situation resulted from
measures close to or below the detection limit, because
this concentration corresponds to approximately 5
times the IC50 for this marker (0.98 ng/mL). A limita-
tion of this study is that the method interassay perfor-
mance could not be evaluated. We considered it unac-
ceptable to collect enough blood (i.e., 3  50 mL)
during a single collection from a healthy individual to
run the whole assay at least 3 times, and PBMCs cannot
be kept over 3 days without cell culture, which artifi-
cially changes the expression of our markers and in-
creases interassay imprecision. Instead, we measured
intrapatient variability by sampling 3 healthy volun-
teers weekly over 3 weeks, which is ethically more ac-
ceptable and encompasses both physiological and ana-
lytical time-dependent variability. With the exception
of NFAT1 at IC50 TAC concentration (CV 50%), in-
trapatient variability was 20% for all the pharmaco-
dynamic parameters, suggesting that the basal concen-
trations of these biomarkers, as well as the residual
values obtained atmaximal inhibition, are rather stable
Table 2. Physiological expression of biomarkers
along the calcineurin pathway and response
variability to tacrolimus inhibition.
PD biomarker n
I0 (log10-
transformed)
Imax (log10-
transformed)
Geometric
mean CV (%)
Geometric
mean CV (%)
NFAT1 (MFI)a 24b 794.3 16.5 251.2 14.3
IL-2CD4 (%) 32 39.8 11.0 0.3 70.6
IL-2CD8 (%) 32 12.6 20.0 0.5 195
CD25CD3 (%) 12b 39.8 11.2 31.6 13.9
a MFI, mean fluorescence intensity.
b Reduced n due to technical failures.
Table 3. Pharmacodynamic response to increasing
concentrations of TAC and interindividual
variability.
PD biomarker
IC50
Geometric
mean
(ng/mL)
Range
(ng/mL)
CV of log10
transformed
data (%)
NFAT1 (MFI)a 0.49 0.25b–7.24 226
IL-2CD4 (%) 0.56 0.18b–13.49 449
IL-2CD8 (%) 0.98 0.25b–16.60 7446
CD25CD3 (%) 1.74 0.25–21.38 270
a MFI, mean fluorescence intensity.
b Limit of detection of the corresponding assay.
Fig. 2. Nonnormalized and I0-normalized concentration–
response curves of mean fluorescence intensity of
NFAT1 in PBMC nuclei.
(A), NFAT1 nuclear translocation inhibition in PBMCs. (B),
I/I0 NFAT1 nuclear translocation inhibition in PBMCs. MFI,
mean fluorescence intensity.
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with time in healthy volunteers. The results are also in
favor of even lower interassay imprecision.
The interindividual variability of I0 in PBMCs is
quite similar to what other authors reported for IL-2
(4, 14–16), and that for CD25 in CD3 was almost 3
times less (4). However, our data were log-transformed
to comply with normal distribution, which was appar-
ently not the case in previous reports.
Imax interindividual variability was low for NFAT1
and CD25, the 2 incompletely inhibited biomarkers,
but much higher for IL-2 in CD4 or CD8 T cells,
whose concentrations were very close to the flow cy-
tometry detection limit. Tacrolimus potencymeasured
as the IC50, a determinant of drug effect, was much
more variable with time and between subjects. How-
ever, this parameter can be derived only from full con-
centration–response profiles and hence cannot be
measured in patients already on CNIs.
Another important finding is the increasing IC50
mean values along the CaN cascade.Moreover, NFAT1
nuclear translocation and CD25 expression could not
be fully inhibited (4, 17), contrary to what was previ-
ously seen for IL-2 expression (5 ). This partial inhibi-
tion of NFAT1 nuclear translocation (Imax range 17%–
83%) suggesting incomplete signal transduction is in
line with previous reports of incomplete CaN activity
inhibition in vivo, even at TAC peak concentrations
(40%–80%of residual enzyme activity) (5, 16, 18, 19).
Furthermore, Sommerer et al. reported that in kidney
transplant recipients on cyclosporine, the inhibition of
NFAT gene expression ranged from nearly complete to
approximately 50%, whereas in patients on TAC the
Imax response was always incomplete despite doses en-
suring clinical rejection prophylaxis (7 ), suggesting the
influence of other factors in TAC immunomodulation
activity (4, 5, 7, 16, 17).
Higher CNI doses are required to suppress the
CD8 than the CD8 T cell subset (16, 20). Further-
more, IL-2 productionmay be constitutively higher, or
less sensitive to CNIs in patients with rejection (4 ), in
Table 4. Polymorphism influence on PD markers and parameters.
PD parameter and
marker Associated SNPa Genetic model Modulation  (SD)
P (univariate
model)
Bonferroni-corrected
P (multivariate
model)b
I0
NFAT1PBMC nuclei None Not applicable NS NS NS
IL-2CD4 Haplotype IL2RA,
rs4646999 JUN
AAT vs ATC 1 0.35 (0.10) 0.001 0.0119
GTC vs ATC 1 0.29 (0.09) 0.005 0.0600
AG-AA vs GG 1 0.28 (0.12) 0.033 0.3960
IL-2CD8 rs4646999 JUN AG-AA vs GG 1 0.44 (0.18) 0.021 0.3180
CD25CD3 Haplotype IL2RA AAT vs ATC 2 0.48 (0.06) 0.001 0.0119
GTC vs ATC 2 0.27 (0.07) 0.015 0.1850
IC50
NFAT1PBMC nuclei rs8177826 PPIA G vs C 2 1.44 (0.43) 0.004 0.0420
IL-2CD4 None Not applicable NS NS NS
IL-2CD8 rs2760501 JUN G vs T 2 1.51 (0.66) 0.006 0.0734
CD25CD3 rs2760501 JUN G vs T 1 2.51 (0.59) 0.035 0.5259
Imax
NFAT1PBMC nuclei rs12885713 CALM1 C vs CT-TT 1 1.00 (0.39) 0.018 0.2214
IL-2CD4
(non–log-transformed)
rs45441997 PPP3CA (GCC)10/10 vs (GCC)8/8 1 0.25 (0.07) 0.002 0.0280
IL-2CD8
(non–log-transformed)
None Not applicable NS NS NS
CD25CD3 Haplotype IL2RA,
rs8177826 PPIA
AAT vs ATC 2 0.75 (0.16) 0.006 0.0720
GTC vs ATC 2 0.26 (0.13) 0.105 1.0000
G vs C 1 0.43 (0.13) 0.024 0.2880
a Haplotype IL2RA: rs10795791, rs11594656, and rs35285258.
b Values in bold are significant at P  0.05.
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accordance with the contributory role of CD8 lym-
phocytes in the cytotoxic response during acute allo-
graft rejection (21). Boleslawski et al. demonstrated
that the frequency of IL-2–expressing CD4 and
CD8 cells correlated positively with CaN activity and
reported that IL-2 expression in25%of CD8T cells
predicted the onset of acute rejection (16). In the pres-
ent study, 5 healthy volunteers (14%), i.e., individuals
with no major immunological conflict, had (stimu-
lated) I0 levels of IL-2
CD8 25%, together with al-
most complete inhibition of IL-2CD8 by TAC (Imax
0.1%–2.6%). On the other hand, 2 other individuals
with I0  19.2 and 23.2% yielded Imax values of 6.4%
and 6.1%, respectively. Interestingly, the NFAT1 Imax
values in the 5 patients with high IL-2CD8 expres-
sion were up to 2-fold higher than those reached in the
rest of the cohort (37% vs 28% on average, P 0.0019
Kruskal–Wallis test).
UnlikeNFAT1 andCD25, IL-2was strongly inhib-
ited by TAC, andmost individual Imax levels were close
to the limit of detection (i.e., 0.18% for IL-2CD4
and 0.25% for IL-2CD8), hence poorly precise. This
is a limitation of flow cytometry in measuring IL-
2CD8 expression as a drug effect biomarker
(16, 21). However, augmented values are expected in
transplant patients because of the immunological con-
flict. Despite this limitation, we observed changes in
IL-2 response to TAC concentrations as low as 0.1
ng/mL (data not shown) in both T cell subsets, as for
the other biomarkers studied here.
Other important findings of this study are the sig-
nificant associations between polymorphisms in genes
coding proteins of the calcineurin pathway and re-
sponses along this pathway to increasing levels of TAC.
Moreover, the percentage of variability explained by
these polymorphisms was quite high, reaching 84% for
CD25 on CD3 cells in stimulated conditions without
TAC (I0). This is the first time that linkage disequilib-
rium between IL2RA (CD25) rs10795791, rs11594656,
and rs35285258 is reported (22–24). This mutated
IL2RA haplotype, where rs10795791 is located in the
upstream region of the IL2RA gene and the other 2
SNPs are intergenic, was associated with lower mem-
brane expression of IL-2R on T cells and higher IL-2
expression in memory CD4 T cells. IL-2R increases
IL-2 affinity for its receptor, allowing cellular response
to the low physiological concentrations of IL-2 in vivo.
IL-2R signaling also induces IL-2 secretion, which in
turn increases and prolongs IL-2R expression, up-
regulating its signaling. In unstimulated conditions,
IL-2 is mainly produced by activated CD4 T helper
cells, whereas during the immune response, activated
CD4 and CD8 T cells produce large amounts of
IL-2, which then acts on CD25 T effector and regula-
tory cells. Furthermore, the promoter region of the
IL2RA gene has 2 positive regulatory regions involved
in the regulation of IL2 transcription, andmutations in
1 or both of these responsive elements lead to the dim-
inution or abrogation of IL2 transcription, respectively
(25). The haplotype elements reported here do not be-
long to the IL2RA promoter region, and contrary to the
abovemutations, were associatedwith augmented IL-2
expression in CD4 T helper cells, which are recruited
first during the cellular immune response. This in-
crease in IL-2 expression despite decreased IL-2R ex-
pression seems paradoxical. However, it should be
noted that the former concerns CD4 T helper cells
and the latter all CD3 cells, which might explain this
apparent discrepancy. Indeed, high IL-2 expression
should be associated with increased activity of regula-
tory T cells (Tregs). Tregs express CD25 constitutively,
but they depend on exogenous sources of IL-2 as they
are unable to produce this cytokine. IL2RA haplotypes
might also regulate the level of expression of CD25 on
Tregs or other immunologically relevant cells (25, 26);
hence, decreased expression of CD25 would be associ-
ated with less robust Treg function. As Tregs prevent
the expansion of CD4, CD8, and natural killer (NK)
lymphocytes, decreased CD25 expression on Tregs
would be consistent with higher activation of CD4
cells in our stimulated conditions (I0). Interestingly,
IL2RA polymorphisms and haplotypes (1 including
rs10795791 and the other rs11594656, although each
associated with 2 different SNPs) have been associated
with several autoimmune diseases (27–37). Of course,
this hypothesis deserves further exploration.
PPP3CA rs45441997 (GCC)10/10 is a 5 untrans-
lated region variation located in the promoter region of
the catalytic subunit of calcineurin. It was associated
here with higher IL-2CD4 Imax (i.e., weaker maxi-
mal inhibitory activity) of TAC and accounted for 23%
of its pharmacodynamic variability. The CaN catalytic
subunit  exerts a critical role in signal transduction
along the pathway. It structurally binds Ca2-
calmodulin and the calcineurin regulatory subunit
during enzyme activation, a process that triggers
NFAT1 dephosphorylation. This mutation in the pro-
moter region of PPP3CA may enhance its transcrip-
tion, inducing higher NFAT dephosphorylation and
translocation to the nucleus, thus resulting in an aug-
mentation of the cytokines produced downstream. As
CD4 T cells are the starters of the immune response,
they may be more sensitive to signal transduction vari-
ations than CD8 cells.
The PPIA rs8177826 CG SNP located in the pro-
moter region of the gene coding cyclophilin A, the intra-
cellular receptor of cyclosporine (and not tacrolimus),
decreases NFAT1 IC50 and explains 37% of its interindi-
vidual variability. It has been previously demonstrated
that 1 of the physiological roles of cyclophilin A is to pro-
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mote the assembly of calcineurin regulatory and catalytic
subunits (38–40). Interestingly, CNIs intercalate with
this complex, causing allosteric restriction and impeding
NFAT dephosphorylation. This mutation may alter the
assembly process of the enzyme subunits, making it less
effective and more responsive to tacrolimus inhibition.
Consistently here, the concentration–response curve
showed a shift to the left.
A limitation of this pharmacogenetic investiga-
tion is the rather small number of healthy volunteers
involved. We used nonparametric statistical tests
and the rather drastic Bonferroni correction for
multiple testing, meaning that the significant associ-
ations found here are statistically reliable (i.e.,5%
false-positive rate). Moreover, ethics committees are
reluctant to authorize the enrollment of large num-
bers of healthy volunteers. Clearly, this investigation
mainly aimed at raising hypotheses that need to be
explored further.
In summary, this study demonstrates the con-
sistency of signal transduction along the calcineurin
pathway: increasing doses of TAC inhibit NFAT1
translocation and IL-2 and CD25 expression follow-
ing I/Imax models; and NFAT1 translocation to the
nucleus is linked to IL-2 and CD25 expression fol-
lowing allosteric sigmoidal models. This study also
suggests strong associations between tacrolimus
pharmacodynamic parameters and polymorphisms
in the genes coding cyclophilin A, calcineurin cata-
lytic subunit, and CD25.
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